You are here: Home » Companies » News
Business Standard

Cipla's newly launched drug to cure severe malaria in young children

The anti-malaria drug now soon will be available in four sub-Saharan countries

Press Trust of India  |  New Delhi 

Cipla, Cipla logo, Cipla headquarters
An employee works at the reception area of Cipla at its headquarters in Mumbai. Photo: Reuters

major in partnership with for Venture (MMV) on Tuesday launched a used for the treatment of severe in young

The company introduced 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS), a life-saving, pre-referral intervention for the of in

The company's RAS 100 mg was recently added to the Global Fund expert review panel's list of quality-assured medicines, while the process of pre-qualification of this medicine moves through its final stages.

"Our endeavour is to make RAS 100 mg available in rural areas in and to national community programmes, notably with the support of international that have already pledged to procure Rectal Artesunate," MD and Global CEO Umang Vohra said in a statement.

The Mumbai-based company's contains 100 mg of Artesunate and is indicated in from 6 months to 6 years.

It was developed with the support of MMV (with UNITAID financing) and will now soon be available in four sub-Saharan countries.

today ended 0.80 per cent down at Rs 565 on the

First Published: Tue, July 25 2017. 17:51 IST